Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2025;32(11):2257-2274.
doi: 10.2174/0929867331666230822102021.

The Effects of Apple Cider Vinegar on Cardiometabolic Risk Factors: A Systematic Review and Meta-analysis of Clinical Trials

Sahar Dadkhah Tehrani  1 , Mahdi Keshani  1 , Mohammad Hossein Rouhani  2 , Seyed Adel Moallem  3   4 , Mohammad Bagherniya  2   5 , Amirhossein Sahebkar  6   7   8
Affiliations
Meta-Analysis

The Effects of Apple Cider Vinegar on Cardiometabolic Risk Factors: A Systematic Review and Meta-analysis of Clinical Trials

Sahar Dadkhah Tehrani et al. Curr Med Chem. 2025.

Abstract

Background: Cardiometabolic syndrome (CMS) is a set of metabolic abnormalities that are risk factors for cardiovascular disease (CVD). Apple cider vinegar (ACV) has been used in several studies as a natural agent to improve CMS risk factors. The present study aimed to perform a systematic review and meta-analysis of the effects of ACV consumption on lipid and glycemic parameters.

Methods: PubMed, Scopus, and ISI Web of Science databases were systematically searched to find clinical trials evaluating the effects of ACV consumption on CMS risk factors.

Results: Overall, 25 clinical trials (33 arms) comprising 1320 adults were entered in this study. ACV consumption could significantly improve the levels of FBG (-21.20 mg/dl; 95% CI: -32.31 to -2.21; I2: 95.8%), HbA1c (-0.91mg/dl; 95% CI: -1.62 to -0.21; I2: 98.9%), and TC (-6.72 mg/dl; 95% CI: -12.91 to -0.53; I2:50.8%). No significant results were observed for BMI, HOMA-IR, serum insulin, TG, LDL-C, and HDL-C. Subgroup analysis showed a significant decrease in FBG, HbA1c, TC, and TG in diabetic patients. In this type of analysis, ACV consumption significantly reduced FBG levels when administered for both duration subgroups (≥12 and <12 weeks). Moreover, in the subgroup analysis based on duration, TG concentration was significantly decreased following ACV consumption for ≥ 12 weeks.

Conclusion: This meta-analysis showed that consumption of ACV has a favorable effect in decreasing some CMS risk factors including FBG, HbA1c, and TC.

Keywords: Apple cider vinegar; HBA1C; cardiometabolic risk factors; cardiometabolic syndrome.; cholesterol; fasting blood glucose.

PubMed Disclaimer

References

    1. Kirk E.P.; Klein S.; Pathogenesis and pathophysiology of the cardiometabolic syndrome. J Clin Hypertens 2009,11(12),761-765 - DOI - PubMed
    1. Mozaffarian D; Benjamin EJ; Go AS; Arnett DK; Blaha MJ; Cushman M; Heart disease and stroke statistics-2015 update: A report from the American Heart Association. Circulation 2015,131(4),e29-e322
    1. Shah K.; Sharma K.; Saxena D.; Editorial: Health technology assessment in cardiovascular diseases. Front Cardiovasc Med 2023,10,1108503 - DOI - PubMed
    1. Cardiovascular diseases (CVDs): World Health Organization (WHO) Available from: https://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-disea...
    1. Timmis A.; Vardas P.; Townsend N.; Torbica A.; Katus H.; De Smedt D.; Gale C.P.; Maggioni A.P.; Petersen S.E.; Huculeci R.; Kazakiewicz D.; de Benito Rubio V.; Ignatiuk B.; Raisi-Estabragh Z.; Pawlak A.; Karagiannidis E.; Treskes R.; Gaita D.; Beltrame J.F.; McConnachie A.; Bardinet I.; Graham I.; Flather M.; Elliott P.; Mossialos E.A.; Weidinger F.; Achenbach S.; Mimoza L.; Artan G.; Aurel D.; Chettibi M.; Hammoudi N.; Vardanyan K.; Pepoyan S.; Sisakian H.; Scherr D.; Siostrzonek P.; Metzer B.; Mustafayev I.; Jahangirov T.; Rustamova Y.; Mitkovskaya N.; Shibeka N.; Stelmashok V.; De Pauw M.; Lancellotti P.; Claeys M.; Kušljugić Z.; Džubur A.; Smajić E.; Tokmakova M.; Traykov V.; Milicic D.; Pasalic M.; Pavasovic S.; Christodoulides T.; Papasavvas I.; Eftychiou C.; Linhart A.; Táborský M.; Hutyra M.; Sørensen J.T.; Andersen M.J.; Kristensen S.D.; Abdelhamid M.; Shokry K.; Kampus P.; Laine M.; Niemelä M.; Iung B.; Cohen A.; Leclercq C.; Trapaidze D.; Etsadashvili K.; Aladashvili A.; Bestehorn K.; Baldus S.; Zeiher A.M.; Kanakakis J.; Patrianakos A.; Chrysohoou C.; Csanádi Z.; Becker D.; Járai Z.; Hrafnkelsdóttir Þ.J.; Maher V.; Crowley J.; Dalton B.; Wolak A.; Assa E.B.; Zafrir B.; Murrone A.; Spaccarotella C.; Urbinati S.; Salim B.; Orazbek S.; Ayan A.; Bajraktari G.; Poniku D.A.; Erkin M.; Saamay A.; Kurban K.; Erglis A.; Jegere S.; Bajare I.; Mohammed M.; Sarkis A.; Saadeh G.; Šlapikas R.; Lapinskas T.; Čelutkienė J.; Ellafi K.; El Ghamari F.; Beissel J.; Banu C.; Felice T.; Xuereb R.; Popovici M.; Lisii D.; Rudi V.; Boskovic A.; Rabrenovic M.; Ztot S.; Abir-Khalil S.; Meeder J.G.; van Rossum A.C.; Elsendoorn M.; Kostov J.; Kostovska E.S.; Kedev S.; Angel K.; Mjølstad O.C.; Bleie Ø.; Gierlotka M.; Dąbrowski R.; Jankowski P.; Baptista S.B.; Ferreira J.; Gil V.; Badila E.; Gaita D.; Popescu B.A.; Shlyakhto E.; Zvartau N.; Kotova E.; Foscoli M.; Zavatta M.; Stojkovic S.; Tesic M.; Juricic S.; Kaliská G.; Hatala R.; Hlivák P.; Fras Z.; Bunc M.; Pernat A.; Cequier Á.; Anguita M.; Muñiz J.; Johansson B.; Platonov P.; Carballo D.; Rüdiger-Stürchler M.; Tanner F.C.; Shebli H.E.; Kabbani S.; Abid L.; Faouzi A.; Abdessalem S.; Aytekin V.; Atar I.; Kovalenko V.; Nesukay E.; Archbold A.; Tayal U.; Wilkinson C.; Kurbanov R.; Fozilov K.; Mirmaksudov M.; Boateng D.; Daval G.; Momotyuk G.; Sebastiao D.; European Society of Cardiology: Cardiovascular disease statistics 2021. Eur Heart J 2022,43(8),716-799 - DOI - PubMed

LinkOut - more resources